Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
- Autores
- Alcazar, Oscar; Achberger, Susan; Aldrich, Wayne; Hu, Zhenbo; Negrotto, Soledad; Saunthararajah, Yogen; Triozzi, Pierre
- Año de publicación
- 2012
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Apoptosis genes, such as TP53 and p16/CDKN2A, that mediate responses to cytotoxic chemotherapy, are frequently nonfunctional in melanoma. Differentiation may be an alternative to apoptosis for inducing melanoma cell cycle exit. Epigenetic mechanisms regulate differentiation, and DNA methylation alterations are associated with the abnormal differentiation of melanoma cells. The effects of the deoxycytidine analogue decitabine (5-aza-2'-deoxycytidine), which depletes DNA methyl transferase 1 (DNMT1), on melanoma differentiation were examined. Treatment of human and murine melanoma cells in vitro with concentrations of decitabine that did not cause apoptosis inhibited proliferation accompanied by cellular differentiation. A decrease in promoter methylation, and increase in expression of the melanocyte late-differentiation driver SOX9, was followed by increases in cyclin-dependent kinase inhibitors (CDKN) p27/CDKN1B and p21/CDKN1A that mediate cell cycle exit with differentiation. Effects were independent of the TP53, p16/CDKN2A and also the BRAF status of the melanoma cells. Resistance, when observed, was pharmacologic, characterized by diminished ability of decitabine to deplete DNMT1. Treatment of murine melanoma models in vivo with intermittent, low-dose decitabine, administered sub-cutaneously to limit high peak drug levels that cause cytotoxicity and increase exposure time for DNMT1 depletion, and with tetrahydrouridine to decrease decitabine metabolism and further increase exposure time, inhibited tumor growth and increased molecular and tumor stromal factors implicated in melanocyte differentiation. Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo. Copyright © 2011 UICC.
Fil: Alcazar, Oscar. Cleveland Clinic Foundation; Estados Unidos
Fil: Achberger, Susan. Cleveland Clinic Foundation; Estados Unidos
Fil: Aldrich, Wayne. Cleveland Clinic Foundation; Estados Unidos
Fil: Hu, Zhenbo. Cleveland Clinic Foundation; Estados Unidos
Fil: Negrotto, Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Cleveland Clinic Foundation; Estados Unidos
Fil: Saunthararajah, Yogen. Cleveland Clinic Foundation; Estados Unidos
Fil: Triozzi, Pierre. Cleveland Clinic Foundation; Estados Unidos - Materia
-
DECITABINE
DIFFERENTIATION
DNA METHYL TRANSFERASE 1
DNMT1
MELANOMA - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/52612
Ver los metadatos del registro completo
id |
CONICETDig_5fc10cbe9ce58f285e194aee12e0b31a |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/52612 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivoAlcazar, OscarAchberger, SusanAldrich, WayneHu, ZhenboNegrotto, SoledadSaunthararajah, YogenTriozzi, PierreDECITABINEDIFFERENTIATIONDNA METHYL TRANSFERASE 1DNMT1MELANOMAhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Apoptosis genes, such as TP53 and p16/CDKN2A, that mediate responses to cytotoxic chemotherapy, are frequently nonfunctional in melanoma. Differentiation may be an alternative to apoptosis for inducing melanoma cell cycle exit. Epigenetic mechanisms regulate differentiation, and DNA methylation alterations are associated with the abnormal differentiation of melanoma cells. The effects of the deoxycytidine analogue decitabine (5-aza-2'-deoxycytidine), which depletes DNA methyl transferase 1 (DNMT1), on melanoma differentiation were examined. Treatment of human and murine melanoma cells in vitro with concentrations of decitabine that did not cause apoptosis inhibited proliferation accompanied by cellular differentiation. A decrease in promoter methylation, and increase in expression of the melanocyte late-differentiation driver SOX9, was followed by increases in cyclin-dependent kinase inhibitors (CDKN) p27/CDKN1B and p21/CDKN1A that mediate cell cycle exit with differentiation. Effects were independent of the TP53, p16/CDKN2A and also the BRAF status of the melanoma cells. Resistance, when observed, was pharmacologic, characterized by diminished ability of decitabine to deplete DNMT1. Treatment of murine melanoma models in vivo with intermittent, low-dose decitabine, administered sub-cutaneously to limit high peak drug levels that cause cytotoxicity and increase exposure time for DNMT1 depletion, and with tetrahydrouridine to decrease decitabine metabolism and further increase exposure time, inhibited tumor growth and increased molecular and tumor stromal factors implicated in melanocyte differentiation. Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo. Copyright © 2011 UICC.Fil: Alcazar, Oscar. Cleveland Clinic Foundation; Estados UnidosFil: Achberger, Susan. Cleveland Clinic Foundation; Estados UnidosFil: Aldrich, Wayne. Cleveland Clinic Foundation; Estados UnidosFil: Hu, Zhenbo. Cleveland Clinic Foundation; Estados UnidosFil: Negrotto, Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Cleveland Clinic Foundation; Estados UnidosFil: Saunthararajah, Yogen. Cleveland Clinic Foundation; Estados UnidosFil: Triozzi, Pierre. Cleveland Clinic Foundation; Estados UnidosJohn Wiley & Sons Inc2012-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/52612Alcazar, Oscar; Achberger, Susan; Aldrich, Wayne; Hu, Zhenbo; Negrotto, Soledad; et al.; Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo; John Wiley & Sons Inc; International Journal of Cancer. Journal International du Cancer; 131; 1; 7-2012; 18-290020-7136CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1002/ijc.26320info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.26320info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454528/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:04:43Zoai:ri.conicet.gov.ar:11336/52612instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:04:44.155CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo |
title |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo |
spellingShingle |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo Alcazar, Oscar DECITABINE DIFFERENTIATION DNA METHYL TRANSFERASE 1 DNMT1 MELANOMA |
title_short |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo |
title_full |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo |
title_fullStr |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo |
title_full_unstemmed |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo |
title_sort |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo |
dc.creator.none.fl_str_mv |
Alcazar, Oscar Achberger, Susan Aldrich, Wayne Hu, Zhenbo Negrotto, Soledad Saunthararajah, Yogen Triozzi, Pierre |
author |
Alcazar, Oscar |
author_facet |
Alcazar, Oscar Achberger, Susan Aldrich, Wayne Hu, Zhenbo Negrotto, Soledad Saunthararajah, Yogen Triozzi, Pierre |
author_role |
author |
author2 |
Achberger, Susan Aldrich, Wayne Hu, Zhenbo Negrotto, Soledad Saunthararajah, Yogen Triozzi, Pierre |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
DECITABINE DIFFERENTIATION DNA METHYL TRANSFERASE 1 DNMT1 MELANOMA |
topic |
DECITABINE DIFFERENTIATION DNA METHYL TRANSFERASE 1 DNMT1 MELANOMA |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Apoptosis genes, such as TP53 and p16/CDKN2A, that mediate responses to cytotoxic chemotherapy, are frequently nonfunctional in melanoma. Differentiation may be an alternative to apoptosis for inducing melanoma cell cycle exit. Epigenetic mechanisms regulate differentiation, and DNA methylation alterations are associated with the abnormal differentiation of melanoma cells. The effects of the deoxycytidine analogue decitabine (5-aza-2'-deoxycytidine), which depletes DNA methyl transferase 1 (DNMT1), on melanoma differentiation were examined. Treatment of human and murine melanoma cells in vitro with concentrations of decitabine that did not cause apoptosis inhibited proliferation accompanied by cellular differentiation. A decrease in promoter methylation, and increase in expression of the melanocyte late-differentiation driver SOX9, was followed by increases in cyclin-dependent kinase inhibitors (CDKN) p27/CDKN1B and p21/CDKN1A that mediate cell cycle exit with differentiation. Effects were independent of the TP53, p16/CDKN2A and also the BRAF status of the melanoma cells. Resistance, when observed, was pharmacologic, characterized by diminished ability of decitabine to deplete DNMT1. Treatment of murine melanoma models in vivo with intermittent, low-dose decitabine, administered sub-cutaneously to limit high peak drug levels that cause cytotoxicity and increase exposure time for DNMT1 depletion, and with tetrahydrouridine to decrease decitabine metabolism and further increase exposure time, inhibited tumor growth and increased molecular and tumor stromal factors implicated in melanocyte differentiation. Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo. Copyright © 2011 UICC. Fil: Alcazar, Oscar. Cleveland Clinic Foundation; Estados Unidos Fil: Achberger, Susan. Cleveland Clinic Foundation; Estados Unidos Fil: Aldrich, Wayne. Cleveland Clinic Foundation; Estados Unidos Fil: Hu, Zhenbo. Cleveland Clinic Foundation; Estados Unidos Fil: Negrotto, Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Cleveland Clinic Foundation; Estados Unidos Fil: Saunthararajah, Yogen. Cleveland Clinic Foundation; Estados Unidos Fil: Triozzi, Pierre. Cleveland Clinic Foundation; Estados Unidos |
description |
Apoptosis genes, such as TP53 and p16/CDKN2A, that mediate responses to cytotoxic chemotherapy, are frequently nonfunctional in melanoma. Differentiation may be an alternative to apoptosis for inducing melanoma cell cycle exit. Epigenetic mechanisms regulate differentiation, and DNA methylation alterations are associated with the abnormal differentiation of melanoma cells. The effects of the deoxycytidine analogue decitabine (5-aza-2'-deoxycytidine), which depletes DNA methyl transferase 1 (DNMT1), on melanoma differentiation were examined. Treatment of human and murine melanoma cells in vitro with concentrations of decitabine that did not cause apoptosis inhibited proliferation accompanied by cellular differentiation. A decrease in promoter methylation, and increase in expression of the melanocyte late-differentiation driver SOX9, was followed by increases in cyclin-dependent kinase inhibitors (CDKN) p27/CDKN1B and p21/CDKN1A that mediate cell cycle exit with differentiation. Effects were independent of the TP53, p16/CDKN2A and also the BRAF status of the melanoma cells. Resistance, when observed, was pharmacologic, characterized by diminished ability of decitabine to deplete DNMT1. Treatment of murine melanoma models in vivo with intermittent, low-dose decitabine, administered sub-cutaneously to limit high peak drug levels that cause cytotoxicity and increase exposure time for DNMT1 depletion, and with tetrahydrouridine to decrease decitabine metabolism and further increase exposure time, inhibited tumor growth and increased molecular and tumor stromal factors implicated in melanocyte differentiation. Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo. Copyright © 2011 UICC. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-07 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/52612 Alcazar, Oscar; Achberger, Susan; Aldrich, Wayne; Hu, Zhenbo; Negrotto, Soledad; et al.; Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo; John Wiley & Sons Inc; International Journal of Cancer. Journal International du Cancer; 131; 1; 7-2012; 18-29 0020-7136 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/52612 |
identifier_str_mv |
Alcazar, Oscar; Achberger, Susan; Aldrich, Wayne; Hu, Zhenbo; Negrotto, Soledad; et al.; Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo; John Wiley & Sons Inc; International Journal of Cancer. Journal International du Cancer; 131; 1; 7-2012; 18-29 0020-7136 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1002/ijc.26320 info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.26320 info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454528/ |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
John Wiley & Sons Inc |
publisher.none.fl_str_mv |
John Wiley & Sons Inc |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613875529416704 |
score |
13.070432 |